Former TJ DaRenTang Chairman Zhang Mingrui has taken over as General Manager of Hainan Huluwa Pharmaceutical Group, responsible for the company's overall Operation work | Quick read announcement
① Former TJ DaRenTang Chairman Zhang Mingrui has been appointed General Manager of Hainan Huluwa Pharmaceutical Group. Company sources indicate, "Chairman Liu Jingping will primarily focus on the work related to the Board of Directors in the future, while General Manager Zhang Mingrui will be responsible for the company's overall Operation." ② Company sources also noted that this year marks the year of Hainan's customs closure, and the company is facing significant opportunities for strategic development. The company's invitation for Mr. Zhang is also strategical.
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Difficult to recover equity transfer funds. Harbin Gloria Pharmaceuticals' PD-1 "divestiture" lawsuit may face a second instance | Quick Reading of Announcement.
① After winning the first instance, Harbin Gloria Pharmaceuticals has further developments in the lawsuit regarding the separation of Innovative Drugs assets. ② The acquiring party, Puxing Puli, has filed an appeal, requesting a ruling that it is not required to pay any penalties to Harbin Gloria Pharmaceuticals.
To extend its Industry Chain layout, Sansure Biotech Inc. intends to acquire 54% equity in Hong'an Jiyuan, which has not yet turned a profit.
①Sansure Biotech Inc. stated that the company values the product's ease of operation, good stability, and high cost performance of Hong'an Jiyuan, making it suitable for projects in grassroots Medical Institutions; ②Since the launch of related products from Hong'an Jiyuan in 2024, thousands of blood analyzers have been installed in various provinces across the country within one year.
Huawei will release AI pathology models, and the Medical Industry is迎来 an important opportunity for intelligent upgrades.
① Huawei's data storage public account released information stating that it will launch the Ruijin pathological model based on the Huawei DCS AI solution. ② Jianghai Securities pointed out that under the guidance of the Health China 2030 Global Strategy, the Medical Industry is ushering in an important opportunity for intelligent upgrades.
A new generic version of enteric-coated esomeprazole has been approved, breaking Livzon Pharmaceutical Group Inc.'s monopoly on this exclusive large product worth "1.3 billion+".
① CSPC PHARMA's Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.'s Aplrazole enteric-coated tablets have recently been approved, breaking Livzon Pharmaceutical Group Inc.'s monopoly in this drug field; ② Industry experts believe that a price war in the Aplrazole enteric-coated tablet market is only possible when the number of approved companies reaches four or more.